🇺🇸 FDA
Pipeline program

GTX/UX Diluent and Flush Solution, GTX-102, ELLIOTTS B SOLUTION (buffered intrathecal electrolyte/dextrose injection)

GTX-102-CL302

Phase 3 small_molecule active

Quick answer

GTX/UX Diluent and Flush Solution, GTX-102, ELLIOTTS B SOLUTION (buffered intrathecal electrolyte/dextrose injection) for Angelman Syndrome is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Angelman Syndrome
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials